Wells Fargo & Company Cuts Avantor (NYSE:AVTR) Price Target to $25.00

Avantor (NYSE:AVTR) had its target price cut by Wells Fargo & Company from $28.00 to $25.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities research analysts have also commented on AVTR. Barclays reduced their price objective on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Monday. Stifel Nicolaus reduced their price objective on shares of Avantor from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. UBS Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Robert W. Baird reduced their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Finally, Raymond James reduced their price objective on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Trading Down 1.8 %

AVTR opened at $18.06 on Monday. Avantor has a fifty-two week low of $18.00 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm has a market capitalization of $12.29 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 3.87 and a beta of 1.28. The company’s 50 day moving average price is $21.63 and its two-hundred day moving average price is $23.39.

Avantor (NYSE:AVTR) last posted its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter last year, the business posted $0.22 EPS. As a group, research analysts predict that Avantor will post 0.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AVTR. MassMutual Private Wealth & Trust FSB raised its holdings in Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after buying an additional 625 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after buying an additional 830 shares during the last quarter. UMB Bank n.a. acquired a new position in Avantor during the third quarter worth $49,000. Global Retirement Partners LLC raised its holdings in Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after buying an additional 1,067 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.